Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 7Carcinoma, Merkel Cell 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Recurrence 3Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Turcot syndrome 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Cancer Resectable 1Non-Muscle Invasive Bladder Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Microsatellite Instability 1

Interventions

Rituximab 2pembrolizumab 1merphos 1avelumab 1apatinib 1Zidovudine 1Valganciclovir 1Tegafur 1Mitomycin 1Methotrexate 1Leucovorin 1Hydroxyurea 1Epirubicin 1Doxorubicin 1Cisplatin 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Epstein-Barr Virus Infections × avelumab × Clear all
NCT02875613 2024-08-28

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

University of California, San Diego

Phase 2 Terminated
6 enrolled 8 charts
Head & Neck

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡